Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.43 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29934771 | 1.00 | IKBKB (0.61) | IKBKBKDM4EPPARDPPARATLR8 | |
| SCHEMBL22263501 | 0.85 | PPARD (0.47) | IKBKBKDM4EPPARDPPARATLR8 | |
| SCHEMBL3715949 | 0.85 | KDM4E (0.56) | IKBKBKDM4EPPARDPPARAMAPT | |
| SCHEMBL31423348 | 0.85 | KDM4E (0.56) | IKBKBKDM4EPPARDPPARAMAPT | |
| SCHEMBL6603045 | 0.84 | KDM4E (0.51) | IKBKBKDM4EPPARDPPARAMAPT | |
| SCHEMBL15564276 | 0.83 | IKBKB (0.45) | IKBKBKDM4EPPARDPPARATLR8 | |
| SCHEMBL15563826 | 0.83 | ALDH1A1 (0.52) | IKBKBKDM4EPPARDPPARAMAPT | |
| SCHEMBL2913722 | 0.83 | ALDH1A1 (0.57) | IKBKBKDM4EPPARATLR8SMN1; SMN2 | |
| SCHEMBL15945346 | 0.81 | SMN1; SMN2 (0.50) | IKBKBKDM4EPPARDPPARAMAPT | |
| SCHEMBL8130480 | 0.81 | IKBKB (0.58) | IKBKBKDM4EPPARDPPARASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102414190-B | Inhibitors of NF-kB | PROFECTUS BIOSCIENCES INC | 2015-06-03 | — | — | CN | claimed |
| US-8513421-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-08-20 | — | — | US | claimed |
| EP-1412349-A2 | PIPERAZINE OXYQUINOLINE (NAPHTHALINE) PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS | Schering Aktiengesellschaft (DE) | 2004-04-28 | — | — | EP | claimed |
| WO-2002098856-A2 | PIPERAZINE OXYQUINOLINE (NAPHTHALINE) PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-12-12 | — | — | WO | claimed |
| CN-107949559-A | Bicyclic fused heteroaryl or aryl compounds as IRAK4 modulators | 辉瑞公司 | 2018-04-20 | — | — | CN | disclosed |
| CN-102414190-B | Inhibitors of NF-kB | PROFECTUS BIOSCIENCES INC | 2015-06-03 | — | — | CN | disclosed |
| US-20090270450-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-10-29 | — | — | US | disclosed |
| EP-1412349-A2 | PIPERAZINE OXYQUINOLINE (NAPHTHALINE) PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS | Schering Aktiengesellschaft (DE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2002098856-A2 | PIPERAZINE OXYQUINOLINE (NAPHTHALINE) PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270450-A1 | CHEMICAL COMPOUNDS | CSF1R, CSF3R, FLT3 | IKBKB 301/4885KDM4E 1916/4885PPARD 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.